VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 8, 2007) - Pyng Medical Corp. (TSX VENTURE:PYT) is pleased to announce the engagement of QIS Capital (547853 BC Ltd.) as the Company's Investor Relations Consultant.
Pyng's objective is to increase awareness of the Company in the investment community. QIS Capital will bear the responsibility to coordinate Pyng's public and investor relations activities and to communicate specifically with the retail audience. QIS Capital will provide corporate information to its large following of investors and will also communicate the investment merits of the Company through its relationships with newsletter editors, brokers, media, and analysts.
As part of this agreement, Pyng Medical has been granted the opportunity to participate in The Small-cap Conference (www.smallcapconference.ca) to be hosted in Vancouver on March 31, 2007.
QIS Capital (547853 BC Ltd.), an investor relations and small-cap investor research source, is a limited company located in Kamloops, BC. The company is owned and operated by Doren Quinton. Pyng Medical and 547853 BC Ltd. operate at arms length and are independent of one another.
This Investor Relations Agreement covers a period of six months from March - August 2007 at a cost of $2500 per month. 547853 BC Ltd. has also been granted a total of 40,000 options exercisable at $0.36 per share for a period of 2 years. These options will vest on a 25% basis every three months from the effective date of the agreement.
547853 BC Ltd. and its principal shareholders hold either directly or indirectly a total of 35,000 shares of Pyng Medical Corp. 547853 BC Ltd. and its shareholders may purchase shares in Pyng Medical from time to time for investment purposes.
Pyng Medical Corp. is a world-leader in intraosseous infusion with its proprietary award-winning FAST1(TM) Intraosseous Infusion System. The FAST1(TM) is used extensively by the U.S. Department of Defense and by Emergency Medical Services around the globe.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.
FOR FURTHER INFORMATION PLEASE CONTACT:
Pyng Medical Corp.